Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAPS
ISRCTN68222801Phase 3Completed
- Sponsor
- University College London
- Start
- Nov 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in antiphospholipid syndrome (APS), venous thromboembolism (VTE) and systemic lupus erythematosus (SLE) comparing Rivaroxaban with Warfarin control (2 arms). Primary endpoint: Percentage change in endogenous thrombin potential from randomization to day 42. Started Nov 2012; status: completed.
02
Drugs
rivaroxabanwarfarin
03
Conditions
antiphospholipid syndrome (APS)venous thromboembolism (VTE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ISRCTN68222801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68222801.